Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

March 31, 2015 5:40 PM ET


Company Overview of Galleon Pharmaceuticals, Inc.

Company Overview

Galleon Pharmaceuticals, Inc. discovers and develops potential drugs for the treatment of breathing-control conditions associated with surgical anesthesia, drug-induced respiratory depression, pain management, and sleep apnea. It focuses on respiratory depression in the acute care market and sleep apnea in the chronic care market; and ventilator weaning, anesthetic/analgesic-induced respiratory depression, COPD, obesity-hypoventilation syndrome, and other diseases. The company was incorporated in 2003 and is based in Horsham, Pennsylvania.

213 Witmer Road

Horsham, PA 19044

United States

Founded in 2003





Key Executives for Galleon Pharmaceuticals, Inc.

Founder, Chief Executive Officer and President
Chief Technology Officer and Vice President of Chemistry
Head of Bioanalytical Chemistry & DMPK
Head of Biology
Senior Vice President of Drug Discovery
Compensation as of Fiscal Year 2014.

Galleon Pharmaceuticals, Inc. Key Developments

Galleon Pharmaceuticals Announces Publication of Proof-of- Concept Clinical Studies for GAL-021, Projected Use for the Emerging Perioperative Sleep Apnea Epidemic

Galleon Pharmaceuticals announced clinically and statistically significant (p<0.01) results from a double-blind, placebo-controlled clinical proof-of-concept study of its lead investigational compound GAL-021 in normal volunteers. The data were published in the most recent issue of Anesthesiology. The study sought to assess whether GAL-021 stimulated breathing in humans with respiratory depression induced by a potent opioid under conditions common after surgery. Researchers concluded that GAL-021 met or exceeded the study's pre-defined goals of maintaining both respiration and pain control under these conditions, and called for further clinical exploration of the drug's safety and efficacy. GAL-021 is being developed to prevent respiratory complications in surgical patients, including those at higher risk due to sleep apnea. According to a recent report in the New England Journal of Medicine, 25% to 80% of surgical patients have sleep apnea predisposing them to the rapidly emerging perioperative sleep apnea epidemic. The combination of sleep apnea with respiratory depressant drugs such as opioids, sedatives and anesthetics is especially dangerous and complicates care of these patients.

Galleon Pharmaceuticals Demonstrates Successful Clinical Proof-of-Concept for Lead Product from Sleep Apnea Drug-Discovery Platform

Galleon Pharmaceuticals announced a clinically significant outcome in a clinical proof-of-concept study evaluating the ability of its lead investigational drug, GAL-021, to successfully regulate respiratory drive, a key requirement to prevent respiratory complications in high-risk surgical patients. This is the first time a drug has been shown to regulate and protect respiratory drive from drug-induced respiratory depression. In this study, intravenous GAL-021 was able to reverse respiratory depression under challenging conditions including high doses of opioids and elevated carbon-dioxide levels, which can be particularly problematic for post-surgical and sleep apnea patients. The company is actively seeking funding to advance this promising candidate into a broad Phase II program. In the double-blinded, placebo-controlled crossover study, 12 people with both normal and elevated carbon-dioxide levels were given alfentanil, a potent opioid analgesic drug commonly used during surgery. Then two dose-levels of alfentanil and two dose-levels of GAL-021 were administered. In this study, GAL-021 successfully protected against the opioid-induced respiratory depression while not affecting analgesia. The dose-dependent protective effect of GAL-021 was statistically and clinically significant at both low and high doses of alfentanil. GAL-021 was well-tolerated with side effects that did not differ from placebo.

Similar Private Companies By Industry

Company Name Region
Celsis Laboratory Group (New Jersey) Inc. United States
PLx Pharma Inc. United States
Midwest BioResearch LLC United States
NeuroScience, Inc. United States
Neurorecovery, Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Galleon Pharmaceuticals, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at